Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $49
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Xenon Pharmaceuticals (NASDAQ:XENE) but lowers the price target from $50 to $49.

August 09, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush analyst Laura Chico maintains an Outperform rating on Xenon Pharmaceuticals but lowers the price target from $50 to $49.
The Outperform rating suggests continued confidence in Xenon Pharmaceuticals' performance, but the slight reduction in the price target indicates a minor adjustment in expectations. This is likely to have a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100